Phase II Study of Orelabrutinib in Combination With Romiplostim N01 in Patients With Primary Immune Thrombocytopenia (ITP) Who Have Received At Least One Prior Line of Therapy

To evaluate whether orelabrutinib combined with romiplostim N01 can improve the quality of remission, increase the probability of successful drug withdrawal, and prolong the time to treatment failure in patients with primary immune thrombocytopenia (ITP) who have received at least one line of prior therapy.

NCT Number	NCT07400250
Lead Sponsor	Peking Union Medical College Hospital
Conditions	Primary Immune Thrombocytopenia (ITP)
Enrollment	28 participants
Start Date	2026-04-01
Primary Completion	2026-10-01 (estimated)
Study Completion	2028-10-01 (estimated)
Updated on ClinicalTrials.gov	2026-02-10